FUJIFILM SonoSite has announced that it has received the U.S. Food and Drug Administration (FDA) for iViz, its newest medical visualization solution. First launched in the European market, iViz was developed from the ground up to meet the needs of the highly-mobile clinician.
Doctors do not always treat patients in traditional care settings or have easy access to supporting hospital infrastructure; instead they depend on tools that can easily be conducted to help diagnose a patient's condition. iViz is a powerful new solution for the evolving needs of these point-of-care users.
‘FUJIFILM SonoSite has received the U.S. Food and Drug Administration approval for iViz for its newest medical visualization solution. The device is designed to meet the needs of the highly-mobile clinician.’
With the device, doctors can seamlessly access learning resources and patient information, store exam findings, submit reports, and consult with remote providers for near real-time assessment making it especially suited for field use and for the growing area of telemedicine.
"iViz is a revolutionary solution for clinicians and represents a landmark in FUJIFILM SonoSite's innovation. It achieves new levels of image performance and provides unprecedented connectivity in a highly mobile platform. Through iViz, we expand our core mission of increasing access to ultrasound to improve patient care quality and reduce healthcare costs," said Masayuki Higuchi, president and CEO of FUJIFILM SonoSite.
FUJIFILM SonoSite is the disruptive specialist in designing cutting-edge ultrasound tools and world-leading education for access to point-of-care visualization.